Clinical trials: LAM
HIV Infections
'COMBINE-2': Real-world Evidence for Effectiveness of Two Drug Regimen, Antiretroviral Therapy With Integrase Inhibitors Plus a Reverse Transcriptase Inhibitor
Dolutegravir (DTG) is a well-tolerated 2nd generation integrase strand transfer inhibitor (INSTI); rilpivirine (RPV) is a well-tolerated non- nucleoside reverse transcriptase inhibitors (NNRTI) and lamivudine (3TC) is a…
- Trial name
- NCT04019873
- Testing
- Dolutegravir (DTG), Lamivudine (3TC), Rilpivirine (RPV)
- Where
- Spain
- Volunteers
- 774 people
- Sponsor
- ViiV Healthcare
Chronic Hepatitis B
Switch to Tenofovir Versus Continue Lamivudine/Adefovir Treatment in Lamivudine-resistance Chronic Hepatitis B Patients
1. Adefovir add-on therapy is superior to switching to adefovir monotherapy or entecavir 1mg monotherapy for chronic hepatitis B (CHB) patients with lamivudine resistance (LAM-R) 2.
- Trial name
- NCT01491295
- Testing
- Tenofovir disoproxil fumarate, Lamivudine plus adefovir
- Where
- Taiwan
- Volunteers
- 160 people
- Sponsor
- Taipei Veterans General Hospital, Taiwan
Pulmonary Function
A National Registry on Chinese Patients With Lymphangioleiomyomatosis
Pulmonary lymphangioleiomyomatosis (LAM), a disease characterized by diffuse cystic changes in the lung, is a rare disorder that affects almost exclusively women.
- Trial name
- NCT03193892
- Where
- China
- Volunteers
- 1,500 people
- Sponsor
- Peking Union Medical College Hospital
HIV Infections
Effectiveness and Safety of Epivir/Ziagen/Zerit (3TC/ABC/d4T) Versus Epivir/Ziagen/Sustiva (3TC/ABC/EFV) Versus Epivir/Ziagen/Agenerase/Norvir (3TC/ABC/APV/RTV) in HIV Patients Who Have Never Received Treatment
The purpose of this study is to see how effective and safe it is to give 1 of the 3 following treatments to patients who may not have received anti-HIV treatment: 1) lamivudine (3TC)/abacavir (ABC)/stavudine (d4T); 2)…
- Trial name
- NCT00005017
- Testing
- Ritonavir, Abacavir sulfate, Amprenavir
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- Glaxo Wellcome
HIV-1-infection
DTG/3TC vs. BIC/FTC/TAF Maintenance Therapy in People Living With HIV:
The hypothesize that DTG/3TC will be non-inferior to BIC/FTC/TAF with a 4% margin in virologically suppressed HIV-infected patients. The study will allow claiming for Superiority.
- Trial name
- PASO-DOBLE (NCT04884139)
- Testing
- Dolutegravir/Lamivudine as a single pill, Bictegravir/Emtricitabine/Tenofovir alfenamide as a single pill.
- Where
- 33 sites in Spain
- Volunteers
- 554 people
- Sponsor
- Fundacion SEIMC-GESIDA
Hiv, Weight Gain
Can INSTI-associated Weight Gain be Halted or Reversed With a Switch to Doravirine/Lamivudine/Tenofovir DF?
Weight gain with the integrase inhibitors and tenofovir alafenamide has been observed in observational cohorts and randomized controlled clinical trials.
- Trial name
- DeLiTE (NCT04665375)
- Testing
- DOR/3TC/TDF
- Where
- Canada
- Volunteers
- 4 people
- Sponsor
- University Health Network, Toronto
Pediatric Immuno-Tolerant Chronic Hepatitis B
A Study of Pegylated Interferon Alfa-2A in Combination With Lamivudine or Entecavir Compared With Untreated Control Group in Children With Hepatitis B Envelope Antigen (HBeAg)-Positive Chronic Hepatitis B (CHB) in the Immune-Tolerant Phase
This randomized, controlled, parallel group, open-label multicenter study will evaluate the efficacy and safety of a combination of pegylated interferon alfa-2A (Pegasys) plus lamivudine or entecavir compared with an untreated…
- Trial name
- NCT02263079
- Testing
- Entecavir, Lamivudine, Pegylated Interferon Alfa-2A
- Where
- 25 sites in United States, Australia and 10 more
- Volunteers
- 62 people
- Sponsor
- Hoffmann-La Roche
HIV Infections, Pregnancy
A Study to Evaluate the Safety and Tolerance of Nelfinavir (NFV) Given With Zidovudine (ZDV) and Lamivudine (3TC) in HIV-Positive Pregnant Women and Their Infants
The purpose of this study is to see if giving nelfinavir (NFV) plus zidovudine (ZDV) plus lamivudine (3TC) to HIV-positive pregnant women and their babies is safe.
- Trial name
- NCT00000887
- Testing
- Nelfinavir mesylate, Lamivudine, Zidovudine
- Where
- 7 sites in United States
- Volunteers
- 24 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Human Immunodeficiency Virus
Simplification From Tenofovir Plus Lamivudine or Emtricitabine Plus Ritonavir-Boosted-Protease Inhibitor to Ritonavir-Boosted-Atazanavir Plus Lamivudine in Virologically-Suppressed-HIVInfected Adults With Osteopenia
A 48-week, open label, non comparative prospective trial in stable chronic human immunodeficiency virus-infected patients having achieved complete virological suppression for more than 24 weeks (human immunodeficiency virus-1 RNA…
- Trial name
- NCT02652793
- Testing
- Boosted atazanavir, Lamivudine
- Where
- Spain
- Volunteers
- 31 people
- Sponsor
- Judit Pich
HIV Infections
Atazanavir and Lamivudine for Treatment Simplification
Objectives of the study: 1. To verify the safety of the study treatment, defined as the persistent control of the virus' replication at 48 weeks after the simplification to lamivudine + atazanavir with ritonavir. 2.
- Trial name
- AtLaS (NCT00885482)
- Testing
- Lamiduvine (Epivir), Atazanavir (Reyataz), Ritonavir (Norvir)
- Where
- Italy
- Volunteers
- 40 people
- Sponsor
- Catholic University of the Sacred Heart
Infection, Human Immunodeficiency Virus I, HIV-1 Infection
HIV-1 Infection Study of Once a Day Versus Twice a Day Protease Inhibitor in Antiretroviral Treatment Naive Adults
This is a Phase IIIB, 48 Week, multicentre, randomized, open-label, parallel group study comparing the safety and efficacy of fosamprenavir plus ritonavir 1400mg/100mg once-daily to fosamprenavir plus ritonavir 700mg/100mg…
- Trial name
- NCT00450580
- Testing
- fosamprenavir/ritonavir
- Where
- 69 sites in Belgium, France and 7 more
- Volunteers
- 212 people
- Sponsor
- ViiV Healthcare
HIV (Human Immunodeficiency Virus)
Exploration of the Variability of Exposure to Antiretroviral Treatment in Hair With a View to Validating Its Value as a Diagnostic Tool for Partial and/or Total Non-compliance With Treatment
Treatment adherence is defined by compliance with the dosage schedule (i.e., dose per dose and number of doses per day), as well as the duration of administration (i.e., number of days during which the dosage schedule must be…
- Trial name
- HAIROBS (NCT07062614)
- Testing
- Hair sampling and questionnaires answers for Patients with Lamivudine or Emtricitabine treatment
- Where
- France
- Volunteers
- 30 people
- Sponsor
- University Hospital, Toulouse
HIV Infections, AIDS
Rollover Study for Zerit (Stavudine) ER Studies (-096, -099)
The purpose of this study is to compare long-term safety and tolerability of stavudine (d4T) extended release (ER) versus conventional (immediate release [IR]) formulations, each in combination with lamivudine (3TC) and efavirenz…
- Trial name
- NCT00116298
- Testing
- stavudine, efavirenz, lamivudine
- Where
- 63 sites in United States, Argentina and 14 more
- Volunteers
- 900 people
- Sponsor
- Bristol-Myers Squibb
HIV Infections
Virologic and Immunologic Activity of Continued Lamivudine (3TC) vs Delavirdine (DLV) in Combination With Indinavir (IDV) and Zidovudine (ZDV) or Stavudine (d4T) in 3TC-Experienced Subjects
To compare the proportion of patients in the 2 zidovudine (ZDV)-containing arms who have a plasma HIV RNA concentration below the limit of detection (defined as 500 copies/ml or less) at Weeks 20 and 24 [AS PER AMENDMENT 8/24/98…
- Trial name
- NCT00000882
- Testing
- Indinavir sulfate, Delavirdine mesylate, Lamivudine
- Where
- 31 sites in United States, Puerto Rico
- Volunteers
- 300 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV-1 Infection
Safety and Efficacy of a Switch to Doravirine, Tenofovir, Lamivudine (MK-1439A) in Human Immunodeficiency Virus (HIV-1)-Infected Participants Virologically Suppressed on an Anti-retroviral Regimen in Combination With Two Nucleoside Reverse Transcriptase Inhibitors (MK-1439A-024)
The multicenter, open label, randomized study will evaluate the safety and efficacy of a switch to MK-1439A (MK-1439 [doravirine] plus lamivudine and tenofovir disoproxil fumarate) in HIV-1-infected participants virologically…
- Trial name
- DRIVE-SHIFT (NCT02397096)
- Testing
- Doravirine, Tenofovir, Lamivudine, Baseline regimen of ritonavir- or cobicistat-boosted protease inhibitor, Baseline regimen of cobicistat-boosted elvitegravir
- Volunteers
- 673 people
- Sponsor
- Merck Sharp & Dohme LLC
Hepatitis B Virus, Allograft
Risk of Hepatitis B Virus Reactivation in Patients Undergoing Allografting
The purpose of this study is to evaluate the risk of hepatitis B reactivation in patients undergoing allografting.
- Conditions
- Hepatitis B Virus, Allograft, Hematological Malignancies
- Trial name
- NCT00876148
- Where
- Italy
- Sponsor
- Azienda Ospedaliera San Giovanni Battista
Acquired Immunodeficiency Syndrome, HIV Infections
Once-Daily Drug Regimen for HIV-Infected Patients
This study will examine the safety of giving antiviral therapy for HIV infection in a once-daily dosing schedule, and assess how well patients tolerate this regimen.
- Trial name
- NCT00001968
- Testing
- Amprenavir, Ritonavir, Abacavir
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infection, Hepatitis C
An Open Label Study To Evaluate The Safety and Kinetics of Nelfinavir in Subjects With HIV and Hepatitis C
The purpose of this study is to confirm the safety, efficacy and delineate the pharmacokinetic properties of nelfinavir in HIV/ Hepatitis C coinfected subjects with Child Pugh A compensated cirrhosis and or Hepatic fibrosis
- Trial name
- NCT00141284
- Testing
- nelfinavir 1,250 mg twice daily, Zidovudine 300 mg twice daily, Lamivudine 150 mg twice daily
- Where
- 5 sites in United States, Canada
- Volunteers
- 12 people
- Sponsor
- Pfizer
HIV Infections
The Safety and Effectiveness of Zidovudine Plus Lamivudine, Used With and Without 1592U89, in HIV-1 Infected Children Who Have Taken Anti-HIV-1 Drugs
To compare the safety, tolerance, durability of the viral load response and the antiviral activity of the 1592U89/zidovudine(ZDV)/lamivudine (3TC) regimen vs. ZDV/3TC regimen.
- Trial name
- NCT00002391
- Testing
- Abacavir sulfate, Lamivudine, Zidovudine
- Where
- 30 sites in United States
- Sponsor
- Glaxo Wellcome
Malaria, HIV Infections
HIV Protease Inhibitors for the Prevention of Malaria in Ugandan Children
HIV and malaria are major causes of morbidity and mortality in Sub-Saharan Africa and children bear the greatest brunt of both diseases. No single existing intervention is likely to control malaria in Africa.
- Trial name
- PROMOTE-PEDS (NCT00978068)
- Testing
- Lopinavir/Ritonavir (LPV/r), Nevirapine (NVP), Efavirenz (EFV)
- Where
- Uganda
- Volunteers
- 176 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco